Categories: News

Kraig Biocraft Laboratories Expands Operational Footprint in Vietnam

ANN ARBOR, Mich., Aug. 17, 2022 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the Company has now been granted a business license to begin operations in Lam Dong Province.

The newly established business license and facility in Lam Dong Province are part of the Company’s expansion into the Vietnamese highlands, the center of silk production in Vietnam. The highlands of Lam Dong Province offer temperate climates ideal for silkworm rearing and ready access to the cocoon and silk spinning facilities currently producing several hundred metric tons of mundane silk per year.

In June, management from Kraig Labs traveled to Lam Dong for meetings with officials from the Lam Dong Agro-Forestry Research Experiment Center (LAREC) to assess the opportunities to expand silk production into the province and to tour the regional support infrastructure. The LAREC operates as the authority in Vietnamese sericulture, maintaining 47 unique species of Vietnamese silkworms. The LAREC has developed multiple varieties of mulberry, including S7-CB, which has doubled production yields, from about 25-30 metric tons of foliage per hectare, for standard mulberry, to 50-60 tons of foliage per hectare, for the S7-CB mulberry strains. Kraig Labs planted with S7-CB mulberry at its facilities in Quang Nam, which has resulted in similar improvements.

The Company’s Vietnamese headquarters will remain in Quang Nam at its breeding and production center. This facility was recently featured as part of the Company’s behind-the-scenes video series, www.kraiglabs.com/videos. The Quang Nam facility is designed to produce and supply all of the Company’s proprietary silkworm eggs for in-house and 3rd party contract manufacturing.

“Lam Dong is the center of silk production in Vietnam. We are pleased to report that, with the granting of this business license, Kraig Labs and our specialized spider silk silkworm technologies are now being woven into the proud history and bright future of Vietnamese sericulture,” said Company COO Jon Rice.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk-based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could,” “will” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Staff

Recent Posts

Health Care AI Initiative Launched by Paragon Health Institute

New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…

30 minutes ago

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…

30 minutes ago

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

3 hours ago

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

4 hours ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

18 hours ago